摘要
目的:评价更昔洛韦治疗中老年带状疱疹的疗效及安全性。方法:156例中老年带状疱疹患者分为两组,更昔洛韦组静脉滴注更昔洛韦0.25g,每日1次;阿昔洛韦组静脉滴注阿昔洛韦0.5g,每日2次。两组疗程均为7d。结果:更昔洛韦组有效率为93.4%,阿昔洛韦组有效率为78.8%,两组比较差异有显著性(P<0.01);患者各项症状、体征消退时间,更昔洛韦组明显较阿昔洛韦组缩短(P<0.01);更昔洛韦组不良反应发生率为6.6%,阿昔洛韦组为13.8%,两组比较差异无显著性(P>0.05)。结论:更昔洛韦治疗中老年带状疱疹安全、速效。
Objective:Thestudywasdesignedtocomparetheefficacyandsafetyofganciclovirandaciclovirforherpeszostertreatmentinmid-agedpatients.Methods:Ganciclovirgroupwassuppliedwithganciclovir0.25gqd.iv,andaciclovirgroup,withaciclovir0.5gbid.iv.Thetherapycoursewas7daysforbothgroups.Results:Atday7afterstoppingtreat-ment,theefficacyofganciclovirwasmoreobviousthanthatofaciclovir(P<0.01)inrelievingsymptomsandsigns.Atthesametime,efficacyassessmentbasedonsymptomscoreshowedthatthetotaleffectiverateofganciclovirandaciclovirgroupwas93.4%and78.8%,respectively.Therewasasignificantdifferencebetweentwogroups(P<0.01).Noseriousadverseeventswererecorded.Conclusion:Ganciclovirisahighlyeffectiveandsafeanti-virusdrugfortreatingmid-agedherpeszoster.犤
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2003年第11期680-681,共2页
Journal of Clinical Dermatology
